We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Google Releases AI Tool for Precision Medicine

By LabMedica International staff writers
Posted on 12 Dec 2017
Google LLC (Mountain View, CA, USA) has announced the open source release of DeepVariant, a deep learning technology to reconstruct the true genome sequence from high-throughput sequencing (HTS) data with significantly greater accuracy than previous classical methods. More...
DeepVariant, which was developed after more than two years of research by the Google Brain team, in collaboration with Verily Life Sciences, transforms the task of variant calling, as this reconstruction problem is known in genomics, into an image classification problem well-suited to Google's existing technology and expertise. Within a year of its development, the deep learning model had won the 2016 PrecisionFDA Truth Challenge award for Highest SNP Performance, outperforming state-of-the-art methods. Since then, the Google Brain team has reduced the error rate by over 50%.

Google has released DeepVariant as open source software to encourage collaboration and accelerate its use in solving real world problems. It has partnered with Google Cloud Platform (GCP) to deploy DeepVariant workflows on GCP in two configurations optimized for low-cost and fast turnarounds using scalable GCP technologies, such as the Pipelines API. This paired set of releases provides a smooth ramp for users to explore and evaluate the capabilities of DeepVariant in their current compute environment, while providing a scalable, cloud-based solution to satisfy the needs of even the largest genomics datasets.

Google hopes that DeepVariant will leverage its computing infrastructure and machine learning expertise to better understand the genome as well as provide deep learning-based genomics tools to the community. The release of DeepVariant as open source software is part of its broader goal to apply Google technologies to healthcare and other scientific applications, and to make the results of these efforts broadly accessible.

Related Links:
Google


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Staining Management Software
DakoLink
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.